Inhaled corticosteroids versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease
21 results
1 - 21Inhaled corticosteroids versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD)
Tiotropium, inhaled steroids and long-acting beta2-agonists alone or in combinations for chronic obstructive pulmonary disease
Combined corticosteroid and long-acting beta-agonist in one inhaler for chronic obstructive pulmonary disease
Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease
Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease
Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus long‐acting beta2‐agonists for chronic obstructive pulmonary disease
Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease: Cochrane systematic review
Once daily long‐acting beta2‐agonists and long‐acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease
Combination inhaled steroid and long‐acting beta2‐agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease
Indacaterol, a once‐daily beta2‐agonist, versus twice‐daily beta2‐agonists or placebo for chronic obstructive pulmonary disease
Inhaled corticosteroids with combination inhaled long‐acting beta2‐agonists and long‐acting muscarinic antagonists for chronic obstructive pulmonary disease
Long‐acting muscarinic antagonists (LAMA) added to combination long‐acting beta2‐agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma
Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long‐acting beta2‐agonists (LABA) for adults with asthma
Combined corticosteroid and long‐acting beta2‐agonist in one inhaler versus placebo for chronic obstructive pulmonary disease
Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD)